Search results
Added:
9 months ago
Added:
1 year ago
Added:
3 months ago
Source:
Radcliffe CVRM
A prespecified secondary analysis of the EAST-AFNET 4 trial has found that the benefits of an early rhythm control strategy for patients with recently diagnosed atrial fibrillation (AF) are maintained regardless of whether patients have obesity or diabetes.¹ These findings suggest that clinicians should not withhold this therapeutic approach based on these common metabolic comorbidities.The…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
The long-term utility of beta-blockers following an uncomplicated myocardial infarction (MI) remains a subject of clinical debate. New secondary results from the AβYSS trial (Assessment of β-blocker interruption one Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization) reveal that interrupting this therapy leads to sustained…
View more
Added:
1 year ago
ESC Congress 2024 — Improved patient-level adherence to guideline recommendations on heart rhythm control through healthcare professional education in patients with atrial fibrillation.Investigator, Dr Dipak Kotecha (University of Birmingham, UK) joins us in London to share key findings from the STEEER-AF study (NCT04396418).This prospective, cluster-randomized international study compared two…
View more
Added:
1 year ago
Added:
1 year ago
Dr Jose Joglar (UT Southwestern, US) joins us virtually to discuss the 2023 guidelines for atrial fibrillation (AF) diagnosis and management.These guidelines are an update to the 2014 document covering the full spectrum of managing patients with AF, from prevention to lifetime interventions, to rhythm and rate control, as well as special populations. A new classification of AF has been created,…
View more
Added:
9 months ago
The Global Impact of AF
Added:
1 day ago
Article
Added:
1 year ago